Protara Therapeutics, Inc. (NASDAQ:TARA – Free Report) – Equities researchers at HC Wainwright decreased their FY2030 earnings per share estimates for shares of Protara Therapeutics in a research note issued to investors on Monday, November 9th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of $1.08 for the year, down from their prior estimate of $1.09. The consensus estimate for Protara Therapeutics’ current full-year earnings is ($1.40) per share.
A number of other research firms have also recently issued reports on TARA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Protara Therapeutics in a research report on Thursday, October 15th. Cantor Fitzgerald reissued an “overweight” rating on shares of Protara Therapeutics in a research note on Thursday, October 15th. Finally, Wall Street Zen raised shares of Protara Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, September 5th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $26.25.
Check Out Our Latest Report on Protara Therapeutics
Protara Therapeutics Stock Performance
Shares of TARA stock opened at $2.51 on Tuesday. The business has a fifty day simple moving average of $3.00 and a 200 day simple moving average of $4.47. Protara Therapeutics has a twelve month low of $2.09 and a twelve month high of $7.82.
Protara Therapeutics (NASDAQ:TARA – Get Free Report) last issued its quarterly earnings results on Friday, November 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.02.
Institutional Trading of Protara Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of America Corp DE increased its holdings in shares of Protara Therapeutics by 86.7% during the first quarter. Bank of America Corp DE now owns 925,918 shares of the company’s stock worth $4,824,000 after buying an additional 430,014 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Protara Therapeutics by 133.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 531,267 shares of the company’s stock valued at $2,767,000 after acquiring an additional 304,110 shares during the last quarter. Walleye Capital LLC lifted its stake in shares of Protara Therapeutics by 204.0% in the 1st quarter. Walleye Capital LLC now owns 443,401 shares of the company’s stock valued at $2,310,000 after acquiring an additional 297,525 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Protara Therapeutics during the 2nd quarter valued at $526,000. Finally, Janus Henderson Group PLC boosted its holdings in shares of Protara Therapeutics by 1.3% during the 1st quarter. Janus Henderson Group PLC now owns 5,207,011 shares of the company’s stock valued at $27,155,000 after acquiring an additional 65,395 shares in the last quarter. Institutional investors own 38.13% of the company’s stock.
Protara Therapeutics Company Profile
Protara Therapeutics, Inc is a clinical-stage biotechnology company focused on developing transformative therapies for cancer and other serious diseases. The company’s lead product candidate, TARA-002, is an investigational cell-based immunotherapy derived from a proprietary preparation of Streptococcus pyogenes. Protara is evaluating TARA-002 primarily for the treatment of non-muscle-invasive bladder cancer.
Protara has also investigated TARA-002 for lymphatic malformations, rare abnormalities of the lymphatic system that can cause swelling, pain and other complications.
Read More
- Five stocks we like better than Protara Therapeutics
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Protara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
